ACR Convergence 2026 Archives - ACR Meeting Abstracts

Abstract Number: 1647

C16 Ceramide as a Key Candidate Sphingolipid in Gout and a Possible Endogenous Primer of Macrophage NLRP3 Alongside Monosodium Urate Crystals
Abstract Number: 0255

C4, but Not C3, Tracks Biologic Mechanism in SLE: Differential Complement Component Recovery Reveals Drug-Specific Pharmacodynamic Signatures
Abstract Number: 0953

Calcinosis Identifies a Vascular-Inflammatory Phenotype Associated with Structural Bone Damage in Systemic Sclerosis
Abstract Number: 1648

Calcium Pyrophosphate Deposition in the Knee and Risk of Total Knee Replacement: a Nationwide Study in Individuals with Prevalent Knee Osteoarthritis
Abstract Number: 0979

CaMKIIa Integrates Calcium Signaling and Oxidative Stress to Promote Fibrosis in Scleroderma Fibroblasts
Abstract Number: 1878

Can a Guideline-Grounded Artificial Intelligence Scribe Support Rheumatology Consultation Prioritization from Patient Narratives? A Feasibility Study
Abstract Number: 2287

Can a Multidisciplinary Model Improve the Management of Complex IBD-SpA Cases? Insights from Gastroenterology-Rheumatology-Pharmacy Multidisciplinary Meetings
Abstract Number: 1690

Can a Robot Measure RA Activity? First Independent Clinical Evaluation of ARTHUR and DIANA
Abstract Number: 2098

Can cluster analysis redefine phenotypes in giant cell arteritis? Data from the ARTESER registry
Abstract Number: 2234

Cancer in Systemic Lupus: Greater Risk in Younger Adults
Abstract Number: 1889

Cancer Risk with Janus Kinase Inhibitors: Drug-Specific Risks or a Class Effect? A systematic literature review and network meta-analysis across Immune Mediated Inflammatory Diseases
Abstract Number: 2056

Cancer Screening Modality Yield in Anti-TIF-1γ Positive Dermatomyositis: A Systematic Review and Meta-Analysis of Diagnostic Performance
Abstract Number: 2832

Candida albicans primes humoral immune responses in rheumatoid arthritis through the hyphal adhesin Als1
Abstract Number: 0752

Capturing Fibroblast Activity and Alveolitis of Autoimmune Interstitial Lung Disease in Vivo: a Paired FAPI-PET/CT and Bronchoalveolar Lavage Exploratory Analysism [Founded by PNRR-MCNT2-2023-12377894]
Abstract Number: 2918

CAR T-Cell Therapy Outcomes in a Non-Hodgkin Lymphoma Cohort With Pre-Existing Systemic Autoimmune Disease
Abstract Number: 2155

CAR-T Cell and CAR-NK Cell Therapy in Systemic Sclerosis: A Systematic Review
Abstract Number: 2773

CAR-T Cell Therapy for Autoimmune Rheumatic Diseases: A Systemic Review and Consensus-Based Recommendations from Taiwan College of Rheumatology
Abstract Number: 0256

CAR-T cell Therapy in SLE: A Pooled Analysis
Abstract Number: 0412

Carbonic Anhydrase Antibody Positivity Is Associated With Clinician-Diagnosed Sjögren’s Disease in SSA/SSB-Negative Patients With Incomplete Objective Testing
Abstract Number: 1880

Cardiac Manifestations in Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Abstract Number: 0753

Cardiac scarring but not active inflammation drives low ejection fraction in isolated cardiac sarcoidosis
Abstract Number: 2923

Cardio- and Cerebrovascular Outcomes, All-Cause Mortality and Premature Death Across Six Immune-Mediated Inflammatory Diseases (IMIDs): a 14 year Hungarian National Cohort Study
Abstract Number: 1588

Cardio-pulmonary exercise test (CPET) performance and the factors associated with it in patients with idiopathic inflammatory myositis (IIM): A cross sectional comparative study
Abstract Number: 0382

Cardiometabolic Comorbidity Burden Across Spondyloarthritis Phenotypes and Subtypes
Abstract Number: 2422

Cardiorenal-Metabolic Comorbidity and Therapy Eligibility in Rheumatoid Arthritis: Real-World Data from the Ontario Best Practices Research Initiative (OBRI)
Abstract Number: 1900

Cardiovascular and Mortality Outcomes with JAK versus TNF Inhibitors in Rheumatoid Arthritis: A Target Trial Emulation
Abstract Number: 1308

Cardiovascular and Safety Outcomes of IL-17 Versus TNF Inhibitors in Ankylosing Spondylitis: A Propensity-Matched Analysis
Abstract Number: 1674

Cardiovascular and Survival Outcomes of ICI-Associated Myositis Compared with Idiopathic Myositis and ICI-Treated Cancer Controls
Abstract Number: 2385

Cardiovascular and Thromboembolic Risks of Selective JAK-1 Inhibitors vs. Pan-JAK Inhibitors
Abstract Number: 2321

Cardiovascular Disease Burden in Inflammatory Bowel Disease Patients With Ankylosing Spondylitis: A Retrospective Cohort Analysis
Abstract Number: 0440

Cardiovascular Impact of Long-Term Low-Dose Glucocorticoid Therapy in Rheumatoid Arthritis: The First Systematic Review with Meta-Analysis
Abstract Number: 0805

Cardiovascular Mortality Among Decedents With Sjögren Syndrome in the United States, 1999-2024: Temporal Trends and Demographic Disparities
Abstract Number: 0441

Cardiovascular Outcomes of Upadacitinib/Baricitinib Versus Tofacitinib in Rheumatoid Arthritis: A Propensity-Matched Retrospective Study
Abstract Number: 0623

Cardiovascular Outcomes with Romosozumab Versus Alendronate in Osteoporosis: A Real-World Propensity-Matched Cohort Study
Abstract Number: 0296

Cardiovascular Risk in SLE Is Concentrated Among Lupus Nephritis and aPL-Positive Subgroups: A Population-Based Inception Cohort Study
Abstract Number: 2386

Cardiovascular Safety of JAK Inhibitors in Younger Adults With Rheumatoid Arthritis: A Propensity-Matched Real-World Analysis
Abstract Number: 0442

Cardiovascular safety of upadacitinib, tofacitinib, and tumor necrosis factor alpha inhibitors in rheumatoid and psoriatic arthritis
Abstract Number: 2387

Carotid Atherosclerosis Assessed by Ultrasound Predicts Treatment Response to Abatacept in Rheumatoid Arthritis
Abstract Number: 2388

Carotid Intima-Media Thickness, Cardiovascular Risk and Ultrasound Synovitis During Tofacitinib Therapy in Rheumatoid Arthritis: A Prospective Longitudinal Study
Abstract Number: 0480

Carotid Plaque Burden Progresses Despite Stable Cardiovascular Risk Factors and Inflammatory Profile in Rheumatoid Arthritis
Abstract Number: 1433

Carotid Ultrasound Improves Cardiovascular Risk Stratification and Predicts Mortality in Rheumatoid Arthritis
Abstract Number: 2489

Case Series: Spine Predominant Juvenile Spondyloarthritis without Sacroiliitis
Abstract Number: 1836

Catching the window for interception in individuals at risk of developing inflammatory arthritis: design of a dynamic “Imminent Risk Score”.
Abstract Number: 2659

Catching What’s Hidden: A Quality Improvement Initiative to Increase Interstitial Lung Disease Screening in Pediatric Rheumatic Diseases
Abstract Number: 0928

CATCR-T Cells for the Antigen-Specific Treatment of ANCA-Associated Vasculitis
Abstract Number: 0806

Cause-Specific Mortality in Incident Systemic Lupus Erythematosus: A Population-Based Cohort Study
Abstract Number: 1101

CBX-663, a First-in-class TCR-mimetic T-Cell Engager Targeting a Telomerase Reverse Transcriptase-derived Peptide-HLA Complex, Depletes B Cells and Monocytes In Vitro and In Vivo and Alleviates SLE Severity in a Preclinical Mouse Model
Abstract Number: 1212

CC312, a Novel CD19/CD3/CD28 Tri-specific T Cell Engager, Demonstrates Sustained SRI-4 responses Beyond One Year Along with Rapid and Deep B-cell Depletion in SLE Patients
Abstract Number: 1931

CCR1-Dependent NK Cell Recruitment Drives KIR2DL4-Mediated Alveolar Injury in Anti-MDA5+ Rapidly Progressive Interstitial Lung Disease
Abstract Number: 2816

CD14 Deficiency in Mice Protects Against Age-associated Mobility Loss, Pain, and Multi-joint Degeneration
Abstract Number: 1902

CD19 CAR T-Cell Therapy in Highly Treatment-Refractory Rheumatoid Arthritis: Phase 1 Results from the COMPARE Trial
Abstract Number: 1938

CD19 Targeted CAR-T Therapy Improves Clinical Outcomes and Reduces Fibrotic Gene Expression and Immune Cell Colocalization in dcSSc Skin
Abstract Number: 0257

CD19/BCMA Dual-Targeted Allogeneic CAR-T Cell Therapy Induces Immune Reset in Active Systemic Lupus Erythematosus
Abstract Number: 0258

CD2-Targeted IL-2 Nanoparticles Combined with Histone Peptides Synergistically Induce Regulatory T Cells That Suppress Lupus Nephritis
Abstract Number: 1964

CD206 Targeting Peptide RP606-30 Given Topically Attenuates Experimental Skin Fibrosis in Mice
Abstract Number: 0122

CD206-Targeted Glucocorticoid Delivery as an Adjunct to Biologic Therapy in Macrophage-Driven Autoimmune Disease: Proof-of-Concept Clinical Evidence and a Mechanistic Rationale for Addressing the Residual Inflammatory Burden of Single-Pathway Cytokine Blockade
Abstract Number: 0997

CD31-Mediated Leukocyte Trafficking as a Therapeutic Target in Murine Neuropsychiatric Lupus
Abstract Number: 0943

CD38+ NK/T cells define responsiveness to Bi-specific T cell engagers in high-risk MAD5+RPILD: a real-world study and immune surveillance analysis
Abstract Number: 2827

CD8 T Cell-Mediated Poly-Perforin Pore Formation Drives Neutrophil Hypercitrullination and T Cell Responses in Rheumatoid Arthritis
Abstract Number: 1983

CD9+ Circulating T Follicular Helper (cTfh) Cells are Expanded in dsDNA Positive Lupus Nephritis
Abstract Number: 2016

Celastrol-Loaded Synthetic High-Density Lipoprotein Nanoparticles Preferentially Target Inflamed Synovial Macrophages and Attenuate Zymosan-Induced Arthritis
Abstract Number: 0128

Cellular and Transcriptional Differences Across Early Sjögren’s Disease Subphenotypes
Abstract Number: 0259

Cenerimod, a selective S1PR1 modulator, induces changes in BCR and TCR repertoire in systemic lupus erythematosus: Post-hoc analysis from the placebo-controlled Phase 2b CARE trial
Abstract Number: 2355

Central sensitization is a major determinant of symptom burden and phenotypic heterogeneity in Sjögren’s disease: an Italian multicenter cross-sectional study
Abstract Number: 1932

Central trained immunity induced by inflammatory arthritis is a link to cardiovascular disease
Abstract Number: 0297

Cervical Cytological Findings and Human Papillomavirus Infection in Systemic Lupus Erythematosus: Frequency and Impact of a Treat to Target (T2T) Strategy in a Spanish Single Center Cohort
Abstract Number: 2389

Challenges and Unmet Needs in the Management of Patients with Rheumatic Disease and Cancer: A Qualitative Study of Multidisciplinary Clinicians
Abstract Number: 1738

Change in Lipoprotein(a) with Tumor Necrosis Factor Inhibitor Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 2645

Changes in Gout Treatment and Outcomes Upon Referral from Primary Care to Rheumatology
Abstract Number: 2774

Changes in HLA-B*58:01 Testing and SCAR Disparities Before and After the 2020 ACR Allopurinol Guidelines
Abstract Number: 1649

Changes in Kidney Function and Serum Urate Level: Large-Scale Longitudinal Analysis of Annual Health Checkups
Abstract Number: 1845

Changes in Treatment Pathways and Pregnancy Outcomes Among Women with Active Lupus Nephritis: A Multi‑registry, Multi‑decade Cohort Study
Abstract Number: 2099

Changing Face of Polyarteritis Nodosa Spectrum: Results of a 20-years Cohort
Abstract Number: 2551

Characteristics of Men with an Atypical Femoral Fracture Compared to Men with a Typical Proximal Femur or Hip Fracture
Abstract Number: 1173

Characteristics of Patients Receiving Nintedanib: A Real-World SSc-ILD Cohort Study in the EUSTAR Registry
Abstract Number: 2322

Characteristics of Sacroiliac Joint MRI Involvement in Axial Spondyloarthritis: insights from the Kuwait Spondyloarthritis National Registry
Abstract Number: 1120

Characteristics, Clinical Features, Histopathology, and Gender-Based Differences in Idiopathic Aortitis: A Systematic Review and Meta-Analysis
Abstract Number: 2689

Characterization and Quantification of Spinal Pathology in Axial Psoriatic Arthritis (AxPsA) by Total Body 18F-FDG PET Imaging: A Paradigm Change for Quantitative Assessment of AxPsA.
Abstract Number: 1121

Characterization of Damage in Relapsing Polychondritis
Abstract Number: 1774

Characterization of Diarrhea Adverse Events with Nerandomilast in Patients with Autoimmune Interstitial Lung Disease and Progressive Pulmonary Fibrosis in the FIBRONEER-ILD Trial
Abstract Number: 2032

Characterization of Protective Autoantibody Fine-Specificities in Patients with Established Rheumatoid Arthritis
Abstract Number: 1775

Characterization of Weight Loss with Nerandomilast in Patients with Autoimmune Interstitial Lung Disease and Progressive Pulmonary Fibrosis in the FIBRONEER-ILD Trial
Abstract Number: 1256

Characterizing Elevated Disease Activity in Systemic Lupus Erythematosus: Results from a Real-World Survey of Rheumatologists in the United States and Europe
Abstract Number: 1183

Characterizing Functional Capacity and Frailty in Systemic Sclerosis Using the Duke Activity Status Index: A Pilot Study
Abstract Number: 1016

Characterizing Memory T Cells Associated with Systemic Lupus Erythematosus Pathogenesis
Abstract Number: 1494

Characterizing Mental Health Burden of Patients with Juvenile Spondylarthritis
Abstract Number: 1337

Characterizing Nociplastic Pain in Axial Spondyloarthritis
Abstract Number: 0722

Characterizing Referral Patterns to Adult Rheumatology Clinics at a Tertiary Academic Health System
Abstract Number: 2235

Characterizing systemic lupus erythematosus associated myocarditis: from rare clinical disease to subclinical involvement
Abstract Number: 2739

Characterizing Systemic Lupus Erythematosus Cohorts in the All of Us Study: Implications for Research
Abstract Number: 0443

Characterizing the mode of action of the oral TNFR1 signal inhibitor, balinatunfib, in rheumatoid arthritis
Abstract Number: 0413

Characterizing the Sjögren’s Disease and Treatment Journey: A Real-World study from the US
Abstract Number: 2049

Chi3L1, A Senescence-Linked Factor And Aging Biomarker, That Drives MSCs Dysfunction Promoting Joint Aging And OA Progression
Abstract Number: 1495

Child Opportunity Index and Longitudinal Disease and Pain Control in Youth with Systemic Lupus Erythematosus
Abstract Number: 1496

Children with Obesity and JIA may Require Higher Adalimumab Dosages: Results from a Prospective, Multicenter Pharmacokinetic Study
Abstract Number: 0111

Choline as a Food-Derived Metabolite Linking Synovitis to Osteoarthritis Progression
Abstract Number: 1776

Chronic Corticosteroid Utilization in Systemic Lupus Erythematosus: A Real-World Claims Analysis
Abstract Number: 1951

Chronic high type I interferon signaling renders mucosal-associated invariant T (MAIT) cells susceptible to apoptosis in lupus
Abstract Number: 0298

Circulating Bacterial Small RNAs are Dynamically Altered from Preclinical to Clinical SLE
Abstract Number: 1906

Circulating Mitochondrial Proteins May Mediate Pain in Lupus Patients Despite Serologically Active DORIS Remission or Non-Arthritic Clinical Activity
Abstract Number: 2033

Circulating protein signatures in rheumatoid arthritis correlate with anti-citrullinated protein antibody and rheumatoid factor serostatus
Abstract Number: 2060

CIT-013 as a Novel Therapeutic Strategy in Rheumatoid Arthritis Through Extracellular Trap Opsonization and Macrophage Modulation
Abstract Number: 2971

Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Promotes Pro-Fibrotic Coronary Endothelial Cell Responses through NF-κB Signaling
Abstract Number: 2034

Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Induces Macrophages to Secrete Mediators that Activate Coronary Endothelial Cells
Abstract Number: 0096

Citrullinated Neutrophil Serine Proteases generate autoantibody responses in individuals at-risk for Rheumatoid Arthritis
Abstract Number: 0889

Cizutamig Induces Deep Depletion of Tissue B Cells and Plasma Cells Across Multiple Autoimmune Diseases with Evidence of Immune Reset
Abstract Number: 1589

CK-AIM: A Clinical Tool to Guide Autoimmune Myopathy Testing and Rheumatology Referral in Patients with Elevated Creatine Kinase
Abstract Number: 2288

Class -Level and Drug -Level Persistence of IL-17Ai versus IL-23 Inhibitors in Psoriatic Arthritis: Results from the PPD CorEvitas PsA/SpA Registry
Abstract Number: 1338

Classification Divergence in Axial Spondyloarthritis: Comparative Performance of ASAS-SPARTAN-2025 and ASAS-2009 Criteria in the Reuma-Check Cohort
Abstract Number: 0559

Classification of Pediatric APS: A Multicenter Evaluation of the 2006 and 2023 Criteria
Abstract Number: 0545

Climbing the Kirkpatrick Ladder: A Decade of Education Scholarship at ACR Annual Meetings
Abstract Number: 1369

ClinESSDAI versus ESSDAI for Assessing Treatment Effects in Sjögren’s Disease: Findings from the Phase 2 DAHLIAS Trial of the FcRn Blocker Nipocalimab
Abstract Number: 2454

Clinical Accuracy, Safety and Completeness of Large Language Models for Pregnancy, Family Planning and Lactation Counseling in Inflammatory Rheumatic Diseases: An Expert-Rated Comparative Study
Abstract Number: 0516

Clinical Activity and Day-15 Immune Reconfiguration After Tandem CD19/BCMA CAR T-Cell Therapy in Refractory Systemic Lupus Erythematosus
Abstract Number: 1370

Clinical and Biologic Implications of Dual ANA and RF Positivity in Sjögren’s Disease
Abstract Number: 2715

Clinical and Economic Outcomes of Psoriatic Arthritis Patients with Overweight or Obesity Treated with Ixekizumab and with Tirzepatide: a Modeling Study
Abstract Number: 0299

Clinical and Immunological Characteristics and Prognostic Model Construction of Patients with Late-Onset Systemic Lupus Erythematosus in China
Abstract Number: 1812

Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients with Microvascular Disease: A Descriptive Analysis of the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository (“Registry”)
Abstract Number: 0932

Clinical and Laboratory Predictors of Recurrent Thrombosis in Patients with Thrombotic Antiphospholipid Syndrome (APS): A Prospective Analysis of the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository (“Registry”)
Abstract Number: 1675

Clinical and Oncologic Outcomes of IL-17 Inhibitor Therapy in Patients Receiving Immune Checkpoint Inhibitors
Abstract Number: 2156

Clinical and pulmonary responses after BCMA-targeted plasma-cell depletion in systemic sclerosis-associated ILD: a case report and focused literature review
Abstract Number: 0414

Clinical and Serologic Features of a Diverse Cohort of Patients with Sjogren’s Disease at a Single Academic Center in New York City
Abstract Number: 2236

Clinical Association of Serum ANCA in SLE and Lupus Nephritis: Meta-Analysis and Systematic Review
Abstract Number: 2237

Clinical characteristics of patients with SLE and anti-interferon-α autoantibodies: an interim analysis
Abstract Number: 0592

Clinical Characteristics and Illness Uncertainty of Patients with UCTD Compared to SLE
Abstract Number: 2666

Clinical Characteristics and Inpatient Outcomes of Adults Hospitalized With Acute Septic Arthritis and Concomitant Gout: A National Inpatient Sample Analysis
Abstract Number: 0837

Clinical Characteristics and Treatment Responses in Adults with PFAPA Syndrome
Abstract Number: 1497

Clinical characteristics associated with progressive interstitial lung disease in juvenile systemic sclerosis: 12-month data from the Juvenile Scleroderma Inception Cohort
Abstract Number: 1498

Clinical characteristics associated with progressive skin involvement in juvenile systemic sclerosis: 12-month data from the Juvenile Scleroderma Inception Cohort
Abstract Number: 0649

Clinical characteristics of anti-OJ positive anti-synthetase syndrome: a single-center experience
Abstract Number: 0383

Clinical Characteristics of Difficult-to-Manage Psoriatic Arthritis: A Single-Center Comparative Cohort Study
Abstract Number: 1892

Clinical Characteristics of Flares of Giant Cell Arteritis: Two-Year Outcomes From the SELECT-GCA Phase 3 Trial
Abstract Number: 0560

Clinical Characteristics of Patients with Pediatric-Onset Rheumatic Disease-Associated Interstitial Lung Disease at Diagnosis: Results from a Single-center Cohort
Abstract Number: 0675

Clinical Characteristics, Outcomes, and Predictors of Progressive Pulmonary Fibrosis in Autoimmune-Associated Interstitial Lung Disease
Abstract Number: 2880

Clinical Characterization of HLA-B*51-Positive Spondyloarthritis Reveals a Distinct Phenotype
Abstract Number: 2609

Clinical Consequences of Mandatory Discontinuation of Compressed Colchicine and Transition to Coated Formulations in Familial Mediterranean Fever
Abstract Number: 0057

Clinical Correlates of Anti-cytokine Antibodies in Patients with Systemic Lupus Erythematosus
Abstract Number: 2490

Clinical Correlates Of Interstitial Lung Disease Patterns In Juvenile Dermatomyositis: A Single-Center Cohort from India
Abstract Number: 0162

CLINICAL COURSE AND RADIOLOGICAL OUTCOMES OF PULMONARY ARTERY THROMBOSIS IN BEHÇET’S DISEASE: A COMPARATIVE STUDY WITH NON-BEHÇET PULMONARY THROMBOSIS
Abstract Number: 1184

Clinical determinants, incidence, and features of interstitial lung disease in anticentromere-positive limited cutaneous systemic sclerosis from the EUSTAR cohort
Abstract Number: 1610

Clinical Development of the Novel Dihydroorotate Dehydrogenase Inhibitor PTC844: Preclinical Studies, Phase 1 Study in Healthy Volunteers, and Design of a Phase 2 Study in Adults with Active Rheumatoid Arthritis
Abstract Number: 2585

Clinical evolution and predictors of the development of clinical manifestations in anti-synthetase syndrome: A longitudinal analysis from the CLASS cohort
Abstract Number: 2610

Clinical Features and Outcomes of 314 Patients with Idiopathic Retroperitoneal Fibrosis / Chronic Periaortitis from 1996-2019
Abstract Number: 1499

Clinical Features and Outcomes of Patients with Juvenile Idiopathic Inflammatory Myopathies and Macrophage Activation Syndrome: A Case Series from a Quaternary Care Center
Abstract Number: 0163

Clinical Features and Risk Factors for Multifocal Fibrosis in Non-IgG4 Related Retroperitoneal Fibrosis: A Systematic Review and Case-Control Analysis
Abstract Number: 2845

Clinical Features of Children Undergoing Brain Biopsy for Suspected Childhood Primary Angiitis of the Central Nervous System: Comparison of Patients With and Without Childhood Primary Angiitis of the Central Nervous System
Abstract Number: 2464

Clinical Global Assessment and Psychiatric Morbidity with Effects on Disease Burden in Patients of Rheumatoid Arthritis: A Multicentric Study
Abstract Number: 0517

Clinical Investigators Advocate for Evolving Lupus Nephritis Clinical Trial Design
Abstract Number: 0415

Clinical Manifestations and Psychological Resilience as Determinants of Patient Empowerment Strategies in Sjögren’s Disease
Abstract Number: 1500

Clinical Manifestations, laboratory features and treatment of children with Syndrome of Undefined Recurrent Fevers: Insights from a large referral center in the United States
Abstract Number: 2552

Clinical Outcomes and Comorbidity Burden After Hip Fracture in Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study
Abstract Number: 1122

Clinical Outcomes and Incidence of Giant cell arteritis-spectrum Events in Korean Patients with Polymyalgia Rheumatica: A Retrospective Multicenter Study Based on a Distributed Research Network Analysis
Abstract Number: 2289

Clinical Outcomes at Week 52 in Male and Female Patients With PsA Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
Abstract Number: 1401

Clinical Outcomes by Baseline Cardiovascular Disease Presence in Patients with Rheumatoid Arthritis Receiving Tocilizumab Treatment: A Post-hoc Analysis of Double-blind, Randomized, Phase 3 Study of Tocilizumab Biosimilar CT-P47
Abstract Number: 2131

Clinical Outcomes by Glucocorticoid Duration in Individuals with Granulomatosis with Polyangiitis and Microscopic Polyangiitis Treated with Avacopan in a Real-World Setting in Two Large Healthcare Systems
Abstract Number: 0300

Clinical Outcomes in SLE Patients with Low-Grade Proteinuria At Risk of Nephritis
Abstract Number: 1213

Clinical Outcomes of Early Treatment Initiation with Belimumab in Patients with SLE: Preliminary Results of RELIABLE
Abstract Number: 1152

Clinical Outcomes of Real-World Avacopan Use in ANCA-associated Vasculitis: A Multicenter, Retrospective, Comparative-Effectiveness Study
Abstract Number: 0676

Clinical Phenotype of Overlapping IgG4-Related Disease and ANCA-Associated Vasculitis: A Multicenter Case Series
Abstract Number: 1813

Clinical Phenotype of Thrombotic Antiphospholipid Patients Not Fulfilling the 2023 ACR/EULAR Criteria
Abstract Number: 2157

Clinical Phenotypes and Treatment Exposure Associated in Relapse After Autologous Stem Cell Transplantation in Systemic Sclerosis: A Single-Center Exploratory Analysis
Abstract Number: 2238

Clinical Phenotypes, Disease Activity Outcomes, and Glucocorticoid Use Among Belimumab- and Anifrolumab-Treated Patients With Non-Renal SLE
Abstract Number: 1885

Clinical Phenotypic Associations With Histopathology and Immunostaining in IgG4-Related Disease
Abstract Number: 0561

Clinical Predictors of Glucocorticoid Dose and Tapering in Pediatric Lupus Nephritis
Abstract Number: 2901

Clinical Predictors of Mortality Following Respiratory-Related Hospitalization in Progressive Fibrosing Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease: Data from a National Registry
Abstract Number: 0650

Clinical Presentation and Outcomes of African American Patients with Anti-Jo1 Autoantibodies in a Large Urban Health System
Abstract Number: 2611

Clinical Presentation, Treatment, and Outcomes of Idiopathic Inflammatory Orbital Myositis: A Systematic Review and Individual Patient Data Meta-analysis
Abstract Number: 2356

Clinical Profile and Ocular/Salivary Gland Function in Primary Sjögren’s Syndrome: A Descriptive Study from a Tertiary Care Centre
Abstract Number: 0651

Clinical Profile of Patients with Idiopathic Inflammatory Myopathies: Multi-Center Cohort Study
Abstract Number: 1923

Clinical Relevance of Patellofemoral (PF) Osteophytes in Knees Without Radiographic Tibiofemoral Osteoarthritis (OA): Data From Two Cohorts
Abstract Number: 0353

Clinical Remission Rates and Predictors in Patients With Axial Spondyloarthritis Undergoing Biologic Therapy: A Cross-Sectional Study at a Tertiary Hospital in Vietnam
Abstract Number: 1123

Clinical Response and Glucocorticoid Sparing With JAK Inhibitors in Takayasu Arteritis: A Disease-Specific Systematic Review and Meta-analysis.
Abstract Number: 1777

Clinical Utility and Appropriateness of Antinuclear Antibody Testing in a United States Community Hospital
Abstract Number: 0301

Clinical Validation of a Refined Lupus Disease Activity Index Informed by Immune Mediators that Characterizes Clinical and Serological Disease Activity In Systemic Lupus Erythematosus
Abstract Number: 2455

Clinical-Ultrasound Discordance During Pregnancy in Inflammatory Arthritis: A Longitudinal Pilot Study
Abstract Number: 1371

Clinical, Radiologic, and Serologic Predictors of Progression in Sjögren-Associated Interstitial Lung Disease: A Single-Center Study
Abstract Number: 0416

Clinical, serological, and histopathological associations of Raynaud’s phenomenon in patients with Sjogren’s disease
Abstract Number: 2612

Clinically Meaningful Influenza and SARS-CoV-2 Vaccine Responses Following Treatment-Free Window of Obexelimab in patients with IgG4-RD
Abstract Number: 2896

Clinician and Community Health Worker Education and Interactive Engagement Increases Referral of Underrepresented Patients to Lupus Clinical Trials
Abstract Number: 2586

Clinicopathological Features of Systemic Sclerosis-Associated Myopathy: A Comparative Cohort Study with Idiopathic Inflammatory Myopathies
Abstract Number: 2888

Clonal Hematopoiesis is Associated with Cranial and Large Vessel Giant Cell Arteritis
Abstract Number: 0998

Clonal Hematopoiesis Of Indeterminate Potential (CHIP) Somatic Mutations Are Associated With Late Age Of Onset And Epigenetic Remodeling In Systemic Lupus Erythematosus (SLE)
Abstract Number: 0999

Clonal Hematopoiesis of Indeterminate Potential Drives Inflammatory Pathways and Worsen Disease Severity in a Murine Model of Systemic Lupus Erythematosus
Abstract Number: 1822

Clonal hematopoiesis orchestrates Giant Cell Arteritis Disease trajectory and immune landscape: a multicentric and multiomics approach
Abstract Number: 2889

Clonal Lymphoid Vasculitis with Aneurysms and Somatic SYK Rearrangements
Abstract Number: 1908

Cloning and Functional Characterization of Pathogenic Autoantibodies from Systemic Lupus Erythematosus Patients
Abstract Number: 2660

Closing The Post-Fracture Care Gap Through a Comprehensive Fracture Care Program: A Strategic Imperative In The Era Of Managed Care
Abstract Number: 2390

Clustering Profiles of Bioactive Lipids and Prediction of Clinical Response in Rheumatoid Arthritis
Abstract Number: 0735

CMV in Autoimmune Diseases: A Single Center Retrospective Study
Abstract Number: 2242

Co-occurring Nonadherence and Active Inflammation Identify a Socially Vulnerable, High Symptom Burden Subgroup in SLE
Abstract Number: 1778

Coccidiomycosis Screening in Rheumatology Patients at a California Academic Medical Center
Abstract Number: 0228

Cognitive Impairment in Systemic Sclerosis. A Scoping Review
Abstract Number: 1257

Cognitive Symptoms in SLE: Insights from the Subjective Perceived Deficit Questionnaire-20 and the Objective American College of Rheumatology Neuropsychological Battery (ACR-NB) Testing
Abstract Number: 0709

Colchicine Exposure And Cardiovascular Outcomes In Patients With Gout Stratified By High-Sensitivity C-reactive Protein: A Real-World Analysis
Abstract Number: 2613

Colchicine Resistance and Comorbidities in Biologic Selection for Familial Mediterranean Fever
Abstract Number: 2100

Colchicine Safety in Behçet disease : A Real-World Adverse Event Profile
Abstract Number: 0873

Combination of anti-CD20 antibody and anti-C5 eculizumab for the treatment of Complement-Mediated TMA Secondary to SLE: A retrospective cohort study
Abstract Number: 0354

Combination of Targeted Therapies is not associated with a significant increase of serious infections, cancers or deaths compared with targeted monotherapy: data from a nationwide propensity score-matched cohort analysis of 2955 patients initiating a combination of targeted therapy
Abstract Number: 1402

Combination Therapy with Abatacept and Daratumumab in Patients with Active Rheumatoid Arthritis: Phase I Results of the CURACTA Trial
Abstract Number: 1403

Combination Therapy with TNF Inhibitors and JAK Inhibitors in Multi-Drug-Resistant Rheumatoid Arthritis: a case series from the UCLouvain Arthritis Cohort
Abstract Number: 2883

Combinations of Clinical Risk Factors and the MUC5B Promoter Variant for Interstitial Lung Disease Risk in Rheumatoid Arthritis: A Prospective Multicenter Study
Abstract Number: 2865

Combined ANA Pattern and Titer Identify Disease-Specific Phenotypes in 375,875 Multi-Analyte Panel (AVISE CTD) Orders: A Real-World Stratification of Autoantibody Positivity and Connective Tissue Disease
Abstract Number: 1434

Combined Clinical and Genetic Screening Model Identifies Interstitial Lung Disease in Patients with RA
Abstract Number: 0652

Combined intensive resistance and endurance exercise in low-disease activity inflammatory myopathies : A Hospital vs. Community-Based prospective study
Abstract Number: 1000

Combined Rapamycin and Metformin Therapy Attenuates Lupus Manifestations While Mitigating Metabolic Toxicity in MRL/lpr Mice
Abstract Number: 1214

Combined Rituximab and Cyclophosphamide in the treatment of severe Systemic Lupus Erythematosus is associated with accelerated clinical response and steroid-sparing benefit, without increasing the risk of serious adverse events
Abstract Number: 0481

Combined subclinical vascular and cardiac involvement in rheumatoid arthritis is independently associated with systemic inflammation
Abstract Number: 2239

Combining Baseline Chronicity Index and Early Treatment Response to Stratify Long-Term Kidney Risk in Lupus Nephritis
Abstract Number: 2716

Commercial price variation among diagnostic tests for the evaluation of giant cell arteritis
Abstract Number: 2717

Commercial price variation for outpatient joint procedures performed with and without ultrasound guidance
Abstract Number: 0482

Common Disease Activity Phenotypes: An Unsupervised Learning Approach via Principal Component-Based Cluster Analysis in Rheumatoid Arthritis
Abstract Number: 1550

Comorbid Restless Leg Syndrome in Fibromyalgia : A Metabolomic Evidence of Glutamate Dysregulation
Abstract Number: 1185

Comorbidity Burden and Frailty in Systemic Sclerosis: Insights from a Large Cohort of US Veterans
Abstract Number: 2290

Comparable Achievement of ASDAS Major Improvement and Inactive Disease with Tofacitinib and Adalimumab in Axial Spondyloarthritis:Interim analysis of A Real-World Study from a Resource-Limited Setting
Abstract Number: 2323

Comparative Analysis of Instruments Measuring Peripheral Arthritis Activity in Spondyloarthritis: A Measurement Properties Study in 13 RCTs
Abstract Number: 1590

Comparative Cardiovascular and Mortality Outcomes in Anti-Synthetase Syndrome Versus Dermatomyositis: A Multicenter Propensity-Matched Analysis
Abstract Number: 0302

Comparative Clustering Analysis in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE): K-Means vs. Hierarchical Ward Clustering An Integrated Methodological and Clinical Perspective
Abstract Number: 2740

Comparative Effectiveness of Anti-Diabetic Medications on the Risk of Post-Traumatic Osteoarthritis Outcomes
Abstract Number: 0838

Comparative Effectiveness of JAK Inhibitors Versus Abatacept in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A National Multicenter Cohort of 667 Patients
Abstract Number: 2614

Comparative Effectiveness of Risankizumab Versus Tumour Necrosis Factor Inhibitors or Interleukin-17 Inhibitors on Joint Outcomes in Biologic-Naïve Patients With Psoriatic Arthritis: A Global Real-World Study
Abstract Number: 1562

Comparative Effectiveness of Sequential Romosozumab-Denosumab vs. Denosumab Alone on Fracture Risk: A Target Trial Emulation Study
Abstract Number: 1124

Comparative Effectiveness of Tocilizumab and Tumor Necrosis Factor Inhibitors in Takayasu’s Arteritis: Age-Related Differences in Treatment Response
Abstract Number: 1174

Comparative Effectiveness of Tocilizumab vs Nintedanib in Systemic Sclerosis-Associated Interstitial Lung Disease: A Propensity-Matched Real-World Study
Abstract Number: 0355

Comparative effectiveness, safety and drug retention of biosimilar Sandoz-adalimumab versus reference adalimumab in rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis: a real-world cohort study
Abstract Number: 1884

Comparative Effectiveness, Safety, and Drug Retention of Biologic Therapies in Still’s Disease: A Nationwide Real-World Cohort Study
Abstract Number: 1309

Comparative Efficacy and Safety of Upadacitinib Versus Deucravacitinib in Biologic-Naïve Patients with Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
Abstract Number: 2775

Comparative Efficacy and Safety of Voclosporin, Belimumab, and Obinutuzumab in Lupus Nephritis: A Systematic Review and Network Meta-Analysis of 9 Randomized Controlled Trials
Abstract Number: 0384

Comparative Efficacy of Biologic Therapies for Enthesitis, Dactylitis, and ACR50 in Psoriatic Arthritis: A Network Meta-Analysis
Abstract Number: 1676

Comparative Infection Risk with TNF Monoclonal Antibodies Versus Etanercept in Axial Spondyloarthritis: A Real-World Study
Abstract Number: 1846

Comparative Outcomes in Pregnant Patients With Rheumatoid Arthritis Treated With and Without Tumour Necrosis Factor Inhibitors: A Systematic Review and Meta-Analysis.
Abstract Number: 0229

Comparative Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis Versus Liver Cirrhosis
Abstract Number: 0230

Comparative Performance of Different Capillaroscopy Systems: A Blinded Agreement Exercise with Experienced and In-Training Assessors
Abstract Number: 0164

Comparative Performance of Four Frailty Tools in PMR: Outcome Specific Utility for predicting Severe Infection, Disability and Relapse.
Abstract Number: 0930

Comparative Performance of Prognostic Scoring Systems in Pediatric Crescentic Glomerulonephritis
Abstract Number: 0303

Comparative performance of SLEDAI-2K, Easy-BILAG, and SLE-DAS in assessing disease activity
Abstract Number: 1739

Comparative Performance of the PREVENT and PCE Risk Assessment Calculators for Predicting Atherosclerotic Cardiovascular Disease Events in Patients with Systemic Lupus Erythematosus
Abstract Number: 1028

Comparative Proteomic Profile Between Psoriasis Without Musculoskeletal Involvement And Early Psoriatic Arthritis
Abstract Number: 1125

Comparative relapse and glucocorticoid survival rates in contemporary cohorts of patients with polymyalgia rheumatica and giant cell arteritis: Long-term data from a tertiary referral center
Abstract Number: 1611

Comparative Risk of Autoimmune Rheumatic Diseases Among Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors
Abstract Number: 2672

Comparative Risk of Giant Cell Arteritis in Older Adults with Type 2 Diabetes Treated With GLP-1 Receptor Agonists Versus SGLT2 Inhibitors: A Real-World Cohort Study
Abstract Number: 1404

Comparative Risk of Herpes Zoster and Pneumonia Among Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis: A Propensity Score-Matched Analysis of the TriNetX Research Network
Abstract Number: 1677

Comparative Risk of Incident Inflammatory Bowel Disease in Psoriatic Arthritis Treated With IL-17 Inhibitors Versus TNF Inhibitors: A Propensity-Matched Cohort Study
Abstract Number: 0839

Comparative risk of incident malignancy among adults with rheumatoid arthritis or psoriatic arthritis initiating upadacitinib, tofacitinib, or a tumor necrosis factor inhibitor
Abstract Number: 1574

Comparative risk of osteoarthritis and arthroplasty in non-obese patients with type 2 diabetes mellitus treated with GLP-1 receptor agonists or SGLT2 inhibitors
Abstract Number: 2101

Comparative Risk of Pancreatic and Vascular Complications in IgG4-Related Disease Treated with Rituximab Versus Glucocorticoids: A Multicenter Retrospective Real-World Study
Abstract Number: 0444

Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Methotrexate Versus Biologic DMARDs: A Real-World Analysis
Abstract Number: 1405

Comparative Safety of Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors in Older Adults with Rheumatoid Arthritis: A Real-World Propensity-Matched Cohort Study
Abstract Number: 1678

Comparative Steroid Dosing and Duration For The Treatment of Immune-Related Adverse Events Following Immunotherapy in Melanoma Patients
Abstract Number: 0417

Comparative Value of Traditional versus Novel Immune-Inflammatory Indices in Assessing Disease Activity of Sjögren’s Disease: A Multicenter Cohort Study
Abstract Number: 1826

Comparing Abatacept to Usual Care for Preventing Disease Worsening in Recently Diagnosed Limited Juvenile Idiopathic Arthritis
Abstract Number: 1591

Comparing All-Cause Mortality between Opioid and Gabapentinoid Users with Idiopathic Inflammatory Myopathy in a Large International Observational Cohort Study
Abstract Number: 0677

Comparing Cardiovascular Outcomes of Tumor Necrosis Factor Alpha Inhibitors versus Methotrexate in Patients with Cardiac Sarcoidosis: A TriNetX Study
Abstract Number: 0653

Comparing clinical features and survival of anti-MDA5 and anti-synthetase idiopathic inflammatory myopathy in a United States cohort
Abstract Number: 2776

Comparing Levels of Hydroxychloroquine and Its Metabolites in Blood Plasma Versus Tears in Patients with Systemic Lupus Erythematosus
Abstract Number: 0483

Comparing Patterns of Medication Use in Seropositive and Seronegative Rheumatoid Arthritis Patients in a US Veteran population: A Cross-Sectional Study
Abstract Number: 1592

Comparing the Risk of Inpatient Mortality and Non-routine Hospital Discharge between Adult Idiopathic Inflammatory Myopathy and Other Systemic Autoimmune Rheumatic Disease Patients in a Large United States Administrative Claims Database
Abstract Number: 0445

Comparison of Cancer Risk in Patients with Rheumatoid Arthritis Treated with Methotrexate Versus Biologic-DMARDs: A Real-World Analysis
Abstract Number: 2240

Comparison of Cognitive Outcomes Between Young and Older Adults with Systemic Lupus and Cerebrovascular Accidents
Abstract Number: 1799

Comparison of Disease-Specific Versus Non-Disease-Specific Digital Health Applications for Movement Therapy in Axial Spondyloarthritis: A Meta Analysis of Three Randomized Controlled Trials
Abstract Number: 2391

Comparison of Efficacy, Safety and Immunogenicity of DRL_AB (Proposed Abatacept Biosimilar) with Orencia® Administered by the Intravenous route as an Add-on to Methotrexate in Patients with Moderate to Severe Rheumatoid Arthritis: Results from a Randomized Double-Blind Study
Abstract Number: 0418

Comparison of Glandular Tissue Stiffness in Sjögren’s Disease and Hashimoto’s Thyroiditis: An Elastography Study on Salivary and Thyroid Glands
Abstract Number: 0041

Comparison of Molecular Responses to Autologous and Allogeneic CD19 CAR-T Cell Therapy in Systemic Lupus Erythematosus
Abstract Number: 0754

Comparison of Optical Imaging with Tender and Swollen Joints and Musculoskeletal Ultrasound in Assessment of PIP Joints of Systemic Lupus Erythematosus Patients
Abstract Number: 2587

Comparison of Progressive Pulmonary Fibrosis Definitions in Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Impact on 5-Year Transplant-Free Survival
Abstract Number: 0215

Comparison of Rituximab and Tocilizumab for systemic sclerosis interstitial lung disease: a multicentric retrospective propensity score-weighted analysis
Abstract Number: 2132

Comparison of the Associations of Cardiovascular Risk Factors to Vascular and Platelet Biomarkers with Prior Venous Thromboembolism in Granulomatosis with Polyangiitis
Abstract Number: 0304

Comparison of the Lower Threshold of Clinically Meaningful Disease Activity in Cutaneous Lupus Erythematosus Using CLASI-A and CLA-IGA-R
Abstract Number: 1186

Comparison of Warrick Semi-Quantitative Scoring System and GOH Staging Algorithm for Detecting Disease Progression in Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Cohort Study
Abstract Number: 1996

Compartment-Specific RABGAP1L Expression Pathways and Differential Correlation with Systemic Inflammatory Mediators in Patients Across Preclinical and Clinical Systemic Lupus Erythematosus Categories
Abstract Number: 0058

Compartment-Specific TLR7/TLR9 Expression Across Myeloid Cell Subsets Characterizes Active Lupus Nephritis
Abstract Number: 0042

Complement C4 Haplotype and Dysbiosis Influence the Spectrum of Clinical Autoimmunity in Anti-SSA/Ro+ Mothers of Children with Neonatal Lupus
Abstract Number: 0755

Complementary Detection of Syndesmophytes by Sagittal and Coronal Low-Dose CT in Axial Spondyloarthritis: SPACE Cohort Analysis
Abstract Number: 2615

Completed suicide with colchicine in familial Mediterranean fever: demographic, clinical, and post-mortem features
Abstract Number: 1001

Composite CD20/BCMA CAR-T in Refractory Lupus Nephritis: Matched Comparator Outcomes, Paired-Biopsy Tissue Remission and Multi-Omic Mechanisms of Non-Response
Abstract Number: 2840

Composite NET load reflects disease activity and flare risk in systemic lupus erythematosus
Abstract Number: 1102

Comprehensive Efficacy Assessment of Adaptive Immune-targeted Therapies via a Fully Humanized SLE Mouse Model
Abstract Number: 0231

Concomitant Sjögren’s syndrome is associated with more severe visceral disease in systemic sclerosis
Abstract Number: 2241

Confirmatory Factor Analysis of the Hospital Anxiety and Depression Scale in SLE
Abstract Number: 1484

Consensus Metrics to Guide and Track Expansion and Enrichment of the Adult and Pediatric Rheumatology Workforce: Results of a Scoping Review and Modified Delphi Process
Abstract Number: 2588

Consensus On IMNM Nomenclature (COIN) Project: An IMACS and MCTC collaboration.
Abstract Number: 1372

Consensus-Based Good Practice Statements for the Evaluation, Diagnosis, and Monitoring of Patients with Sjögren’s Disease
Abstract Number: 1435

Contemporary rheumatoid arthritis patients are more likely to have a positive screen for anxiety, depression, and/or fibromyalgia than more than one swollen joint
Abstract Number: 0419

Content Validity and Meaningful Improvement of ESSPRI and PROMIS Fatigue Short Form 10a in Primary and Associated Sjogren’s Disease
Abstract Number: 0484

Continuous and Clinically Meaningful RAPID3 Improvement Associated with Weight Loss Among Patients with Rheumatoid Arthritis Initiating GLP-1 Receptor Agonists
Abstract Number: 0196

Contribution of the CALLY index at diagnosis to early prediction of all-cause mortality in patients with ANCA-associated vasculitis
Abstract Number: 2967

Convergent and Divergent Gaps in PMR Education: Findings from a CDC-Funded Multi-Method Needs Assessment
Abstract Number: 1436

Convergent Temporal, Clinical, and Geographic Evidence for Association Between Borrelia and Anti-RA33 Immune Response Identified by Analysis of 148,839 Patients
Abstract Number: 2777

Converting Lemons to Lemonade – How to Preserve Access to Rheumatology Visits Through Same Day Pivots to Telemedicine
Abstract Number: 2492

COPA Syndrome – Clinical Spectrum, Genetic Variants, and Treatment Outcomes: A Systematic Review and Pooled Analysis
Abstract Number: 0922

Coronary Artery Calcification is Common Among Systemic Lupus Erythematosus Patients Classified as Low Cardiovascular Risk by the ACC/AHA PREVENT™ Calculator
Abstract Number: 1339

Coronary Artery Calcium scoring in axial Spondyloarthritis and risk factors associated with it
Abstract Number: 1779

Correlation Between Cumulative Glucocorticoid Dose and Glucocorticoid Toxicity Index in Giant Cell Arteritis: A Real-World Longitudinal Study.
Abstract Number: 1126

Correlation of pulse loss or limb claudication with arterial lesions in Takayasu’s Arteritis
Abstract Number: 1740

Correlations Between Cutaneous Lupus Erythematosus Disease Severity and Quality of Life in a US Multi-Center Real-World Cross-Sectional Study
Abstract Number: 2718

Cost-effectiveness Analysis of Screening for Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus Patients on Hydroxychloroquine
Abstract Number: 0782

Cost-Effectiveness of Metformin, Injectable Tirzepatide, and Oral Semaglutide for Patients with Knee Osteoarthritis and Obesity
Abstract Number: 1406

Cost-effectiveness of tapering biologics in rheumatoid arthritis patients: a real-world, multicenter cohort study
Abstract Number: 2741

COVID-19 Outcomes Among Vaccinated and Unvaccinated Patients Receiving Disease-Modifying Antirheumatic Drugs and Biologic Therapies in a Multihospital System in Central Pennsylvania: Associations with Reduced Mortality and Hospital Length of Stay
Abstract Number: 1575

Coxib and Tell: A Systematic Review and Meta-Analysis of Safety and Efficacy of Polmacoxib in 4,591 Osteoarthritis Patients
Abstract Number: 1041

CP-RhA01 Reduces Stromal Pseudo-Resistance Across Autoimmune Disease Models by Metabolic Decoupling of a Pathological Stromal-Immune Loop
Abstract Number: 2690

Cranial [¹⁸F]FDG-PET/CT Findings in Giant Cell Arteritis: Distribution, Reproducibility, and the Effect of Glucocorticoid Pretreatment
Abstract Number: 1437

Cranial Nerve Involvement in Rheumatoid Arthritis: Clinical and Electrophysiological Evaluation
Abstract Number: 0562

Creating Standardized Letter of Medical Necessity Templates in the Electronic Medical Record to Facilitate Medication Approval and Improve Provider Satisfaction in Pediatric Rheumatology
Abstract Number: 2869

Crisis Phenotypes Predict Mortality and Critical Care Burden in Idiopathic Inflammatory Myopathy
Abstract Number: 1029

Cross-Reactive CD8 T Cells Distinguish Spondyloarthritis from HLA-B27 Risk Alone
Abstract Number: 1718

Cross-Sectional Analysis of Washington State Prior Authorization Response Times 2022-2024
Abstract Number: 0024

Cross-Tissue and Compartmental Single-Cell Profiling Validates PDE4B as a Potential Therapeutic Target in Systemic Sclerosis
Abstract Number: 0356

Crusekitug Treatment Resulted in Improvements in Clinical and Radiographic Outcomes in Ankylosing Spondylitis: 52-Week Results from Phase 3 Study
Abstract Number: 1187

Cryofibrinogenemia as a Potential Biomarker in Systemic Sclerosis: Associations with Interstitial Lung Disease and Pulmonary Vascular Involvement
Abstract Number: 0260

CTA313, a Dual-Target CD19/BCMA Allogeneic (allo-) CAR-TANS Cell Therapy, Induces Durable Remission and Immune Reconstitution in Refractory Systemic Lupus Erythematosus (SLE): A Pooled Analysis of Phase 1 Studies
Abstract Number: 1215

CTA313, CD19/BCMA dual targeted allo-CAR-T cell, Induces Deep B-Cell depletion and Durable Remission in Lupus Nephritis
Abstract Number: 0261

CUG252, a Treg-Selective IL-2, Resets Immune Tolerance and Drives Early Clinical Improvement in Patients with Systemic Lupus Erythematosus
Abstract Number: 1310

Cumulative Days of Musculoskeletal Improvement in Bio-Naïve Patients With PsA With or Without Metabolic Syndrome and Obesity Receiving Risankizumab Through Week 244: Integrated Results From the KEEPsAKE Clinical Trials
Abstract Number: 1915

Cumulative Social Disadvantage and Hospital Outcomes of Children and Youth with Juvenile Idiopathic Arthritis in the United States
Abstract Number: 2017

CX3CR1 and MHCII define four synovial macrophage populations with conserved inflammatory response across rheumatoid arthritis mouse models.
Abstract Number: 2392

Cycling to a Second JAK Inhibitor versus Switching to a TNF Inhibitor After First JAK Inhibitor Failure in Rheumatoid Arthritis: A Real-World Target Trial Emulation
Abstract Number: 1053

Cytokine Profiles and Single-Cell Transcriptomic Analysis of Synovial Fluid: Characterization and Stratification of Rheumatoid Arthritis